TruCBN™ and CBN

TruCBN™ is a non‑hormonal, non‑intoxicating CBN ingredient clinically shown to improve sleep maintenance and reduce nighttime awakenings, delivering melatonin‑comparable benefits in randomized, double‑blind trials while targeting endocannabinoid, TRP, and arousal pathways for smoother, more continuous sleep without next‑day impairment.

TruCBN™ leverages CBN’s unique interactions with cannabinoid, orexin, and TRP pathways to support non-intoxicating sleep maintenance, with peer-reviewed clinical trials in over 1,700 participants confirming significant sleep-quality improvements and a strong, well-characterized safety profile for supplement formulations.

A 2025 AHA analysis and expert warnings from Huberman and Walker reveal melatonin’s narrow benefits and serious long-term safety concerns, driving innovative sleep brands to adopt CBN and TruCBN™ as non-hormonal, clinically validated solutions for safer, more sustainable sleep support.

New AHA data linking chronic melatonin use to a 90% higher risk of heart failure and nearly doubled mortality is accelerating a shift toward CBN, as TruCBN™ emerges as a non-hormonal, clinically backed sleep ingredient that supports deeper, safer, next-day-clear rest.

New research highlights Cannabinol (CBN) as a promising, non-intoxicating solution for restorative sleep, addressing the root causes of sleep issues rather than masking symptoms. FloraWorks’ clinical study and findings from Neuropsychopharmacology validate CBN's efficacy in improving sleep quality and duration, offering a science-backed alternative to traditional sleep aids.

Learn how CBN provides unique opportunities for B2B product innovation in the sleep supplement market

In a groundbreaking development for the cannabinoid industry, FloraWorks has announced the peer-reviewed publication of a pivotal study on their proprietary product, TruCBN™.

Learn about CBN's journey to prominence, its impact on the cannabinoid market, and why it's become the go-to ingredient for natural sleep solutions.

In a groundbreaking development, the revolutionary TruCBN™ study will be presented at the prestigious SLEEP meeting, the premier annual meeting for sleep medicine and research professionals.